Time & location: 12:00 p.m. EST, Virtual
The ongoing Carotids and Minds (CAM) study enrolls community-dwelling patients 50-85 years of age with at least two cardiovascular risk factors with and without carotid atherosclerosis to better understand how asymptomatic carotid disease contributes to cognitive impairment and dementia. The study excludes participants with clinical diagnoses of dementia, recent stroke, and other neurological diseases.
This webcast presented the surprising finding, in initial cross-sectional analyses, that 30% of participants (with no clinical diagnosis of cognitive impairment or dementia) had cognitive deficits and roughly 55% had pTau217 levels indicative of Alzheimer’s disease brain pathology. These data demonstrate that there is a large amount of undiagnosed cognitive impairment and dementia in the vascular population.
The session also addresses whether and how carotid stenosis is associated with Alzheimer’s disease and related dementias (ADRD) risk. This will include specificity of cognitive deficits, structural brain changes and blood biomarkers. Overall, this work challenges clinical dogma, raising the possibility that carotid stenosis is a modifiable risk factor for ADRD.
Learn about:
- The prevalence of undiagnosed cognitive impairment and Alzheimer’s pathology in patients with asymptomatic vascular disease
- The relationship between plasma pTau217 levels and cognitive performance in vascular patients
- Why brain health screening should be considered in vascular care, and how might it influence future clinical guidelines and treatment strategies
Presenter
Craig Weinkauf
Associate Professor
Department of Surgery, University of Arizona
Related Posts
Accelerate Building Custom Spatial Proteomic Panels for New Biological Insights
Ultrasensitive Neuroimmune Biomarker Measurement for Translational Research and Therapeutic Development
Decoding Neurodegeneration: High-plex Spatial Proteomics Reveal Distinct Cell Phenotypes and Pathological Signatures in Parkinson’s and Alzheimer’s Disease
In this webinar, Dr. Birgitt Schuele, Associate Professor (Research) of Pathology at Stanford University, showcases how ultrahigh-plex spatial proteomics is being used to uncover distinct cell phenotypes and pathological signatures…
Understanding the Brain: Advancing Neurodegeneration Research with Ultrahigh-Plex Spatial Proteomics
In this webinar, learn how ultrahigh-plex spatial phenotyping has been applied to neurodegenerative disease research.
p-Tau 205 and p-Tau 212: Emerging Biomarkers for Alzheimer’s Disease Research
Spatial Awareness: AI-powered Profiling of Trillions of Immune Cell Distribution Data Points Reveals Key Predictors of Cancer Recurrence Risk
This webinar highlights a groundbreaking study recently published as a Nature cover story (April 2025). Dr. Joe Yeong will describe how a pre-designed analytical framework—driven by well-defined clinical and scientific…
Multimodal Single-Cell Spatial Transcriptomics and Proteomics to Uncover the Biological Processes Driving Immunotherapy Response and Resistance in Renal Cancer
In this webinar, Dr. Anne-Laure Cattin from the Cancer Dynamics Laboratory at The Francis Crick Institute in London, will share her research on kidney cancer, focusing on the integration of…
Tertiary Lymphoid Structures in Cancer Immunotherapy: Insights and Perspectives
Tertiary lymphoid structures (TLS) have emerged as critical components of the tumor microenvironment, influencing immune responses and clinical outcomes in cancer.